- Conditions
- Macular Degeneration
- Interventions
- Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Central Contact Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 838
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Retinopathy, Diabetic
- Interventions
- Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
- Drug
- Lead sponsor
- Ophthalmic Consultants of the Capital Region
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Troy, New York
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
- Interventions
- filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- NG101 AAV gene therapy
- Genetic
- Lead sponsor
- Elisigen, Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Retinal Disease, Bestrophinopathy, Best Vitelliform Macular Dystrophy, Adult Onset Vitelliform Macular Dystrophy, Autosomal Dominant Vitreoretinalchoroidopathy
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Choroid Neovascularization, Age-Related Macular Degeneration
- Interventions
- AGN 211745, Ranibizumab 500µg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Age Related Macular Degeneration
- Interventions
- HLX04-O, ranibizumab
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more
- Conditions
- Glaucoma
- Interventions
- brimonidine 0.15%
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stargardt Disease
- Interventions
- Not listed
- Lead sponsor
- AAVantgarde Bio Srl
- Industry
- Eligibility
- 8 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- GT005
- Drug
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more
- Conditions
- Retinoblastoma
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, mesna, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- VEGF Trap
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 8
- States / cities
- Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
- Conditions
- Diabetic Retinopathy, Diabetes Complications
- Interventions
- Laser Treatment, PF-04523655 high, PF-04523655 middle, PF-04523655 low
- Procedure · Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 26
- States / cities
- Mesa, Arizona • Meza, Arizona • Peoria, Arizona + 20 more
- Conditions
- Retinoblastoma
- Interventions
- Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Retinoblastoma
- Interventions
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Iptacopan (LNP023), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 22
- States / cities
- Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
- Conditions
- Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Wet Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland